Canagliflozin: How SGLT2 Inhibitors Enhance Kidney Oxygenation in Diabetic Patients

Type 2 diabetes can cause kidney problems, but a class of drugs called SGLT2 (sodium-glucose cotransporter-2) inhibitors is gaining attention for their potential benefits. These drugs help the kidneys remove glucose from the body through urine. Researchers at Osaka Metropolitan University studied how these drugs support kidney health, focusing on canagliflozin.

The research team, led by Associate Professor Katsuhito Mori, used a technique called BOLD (blood oxygenation level-dependent) MRI. This method measures changes in blood oxygen levels and was applied to observe the effects of canagliflozin on kidney oxygenation. They found that after taking canagliflozin for five days, patients showed increased oxygen levels in their kidneys, particularly noticeable the day after starting the medication. This suggests that SGLT2 inhibitors may enhance kidney oxygenation and protect kidney function.

In animal studies, researchers can measure kidney oxygen levels directly using electrodes, but this is not feasible in humans. BOLD MRI offers a non-invasive way to assess kidney oxygenation, which could help in understanding kidney disease better and aid in drug development.

The findings are reported in the journal Frontiers in Endocrinology.